GLG News by Hematologist who treat patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Avastin's recent FDA approval for m-breast cancer ( m-BCA) was lukewarm at best with no overall survival benefit yet and modest PFS data. European regulatory agencies usually require cost efficacy data and more strict data, which are not readily available for Roche/Genetech. The British market is not...

Patients who wish to receive Avastin for breast and lung Cancer will need to pay for it themselves.

Rising costs for care of seniors in physician offices will be made more painful by the reimbursement cuts. Will it impede care of seniors??

Due to possible tumor growth warnings will be attached to the use of erythropoietin agents.

This paper as well as http://content.nejm.org/cgi/content/full/358/26/2765 report the efficacy of an oral anticoagulant type drug that appears to be better & safer than parenteral low molecular weight heparin (LMWH).

Safety concerns continue to be voiced re: the effect of erythropoietin products (Epos) on tumor growth.

Only 1 in 5 physicians use electronic patient records. ( and those are either in University Hospitals, large multispecialty clinics or VA hospitals)

Lapatinib, an oral HER-2 inhibitor, is effective in monotherapy in HER-2+ metastatic breast cancer.

"In summary, THEY showed that the infusion of a clonal population of CD4+ T cells with specificity for a single tumor-associated antigen caused complete regression of a tumor. During regression of the tumor, this clone appears to have induced the patient's own T cells to respond to other antigens of...

Very preliminary but this agent may offer a targeted, more "natural" approach to the MPD's- Polycythemia Vera, Myelofibrosis and Primary thrombocytosis.